Trial Profile
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Taxanes
- Indications Early breast cancer
- Focus Therapeutic Use
- 01 Oct 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 08 Dec 2011 Planned end date changed from 1 Dec 2011 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 01 Jun 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.